VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its BiTAC-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
The findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.
The BiTAC-ADC platform represents a novel approach to antibody-drug conjugates (ADCs), a class of cancer therapeutics that deliver cytotoxic drugs directly to tumor cells. Traditional ADCs can cause off-target toxicity due to premature drug release or uptake in healthy tissues. VERAXA's BiTAC-ADC technology addresses this by using two separate components: a tumor-targeting antibody and a systemically inactive precursor drug. The antibody binds specifically to cancer cells and then activates the precursor drug locally, minimizing exposure to healthy cells.
According to the press release, the proof-of-concept studies used 3D tumor cell spheroids, which mimic the architecture of solid tumors more accurately than traditional 2D cell cultures. The results showed that BiTAC-ADCs achieved potent, dose-dependent killing of breast cancer spheroids while sparing non-cancerous cells. This selectivity is a key advantage over conventional ADCs, which often cause side effects such as peripheral neuropathy, liver toxicity, and bone marrow suppression.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
The company's newsroom provides the latest updates on VRXA at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/QiPhH.
This announcement comes at a critical time for the ADC market, which is projected to grow significantly as more targeted therapies gain approval. By demonstrating a differentiated approach that could reduce toxicity, VERAXA's BiTAC-ADC platform may attract interest from pharmaceutical partners seeking to expand their oncology pipelines. The company's participation in the BIO International Convention underscores its commitment to advancing these technologies through collaboration.
